Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Celldex Therapeutics, Inc. (CLDX)

Celldex Q2 2026 net loss widens to $73.5 million; cash rises to $717.6 million

Negative Impact 3 of 5 earnings Written later

Celldex reported a second-quarter 2026 net loss of $73.5 million, or $(0.94) per share, up from $56.6 million, or $(0.85) per share, a year earlier. Revenue fell to $22 thousand from $730 thousand, and research and development expenses rose to $67.5 million, so the headline measures moved the wrong way for shareholders. Cash, cash equivalents and marketable securities reached $717.6 million, helped by a $323.8 million April 2026 public offering, and the company says this funds planned operations through 2028.

Key points

  • Q2 2026 net loss $73.5 million, or $(0.94) per share, versus $56.6 million, or $(0.85) per share, in Q2 2025
  • Q2 2026 total revenues $22 thousand, versus $730 thousand in Q2 2025; decline tied to lower services under Rockefeller University agreements
  • R&D expenses $67.5 million in Q2 2026, up from $54.2 million; G&A expenses $13.1 million, up from $10.4 million
  • Cash and marketable securities $717.6 million at June 30, 2026, up from $451.5 million at March 31, 2026; the company discontinued its Phase 2 prurigo nodularis study

The filing

CompanyCelldex Therapeutics, Inc. (CLDX)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:01 PM ET
Accession number0001171843-26-005316

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.